Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Kenyon D Ogburn"'
Publikováno v:
SAGE Open Medical Case Reports, Vol 8 (2020)
Gastric and gastroesophageal junction adenocarcinomas have poor prognoses. Ramucirumab is considered a second-line standard of care for patients with these cancers. Patients may develop chemotherapy-induced adverse events, and physicians may benefit
Externí odkaz:
https://doaj.org/article/7f3a5e7a4aac47d6af3b118f50264181
Autor:
Josep M. Llovet, Peter R. Galle, Paolo Abada, Sara Lonardi, Jiri Tomasek, Su Jin Koh, Guido Stirnimann, Richard S. Finn, Masatoshi Kudo, Jean-Marc Phelip, Tae-You Kim, Ryan C. Widau, Mark Karwal, Tsai Sheng Yang, Kenyon D. Ogburn, Denis Pezet, Andrew X. Zhu, Yann Touchefeu, Chunxiao Wang, Kun Liang
Publikováno v:
Galle, Peter R; Kudo, Masatoshi; Llovet, Josep M; Finn, Richard S; Karwal, Mark; Pezet, Denis; Kim, Tae-You; Yang, Tsai-Sheng; Lonardi, Sara; Tomasek, Jiri; Phelip, Jean-Marc; Touchefeu, Yann; Koh, Su-Jin; Stirnimann, Guido; Liang, Kun; Ogburn, Kenyon D; Wang, Chunxiao; Abada, Paolo; Widau, Ryan C and Zhu, Andrew X (2021). Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver international, 41(11), pp. 2759-2767. Wiley 10.1111/liv.14994
BACKGROUND & AIMS Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying aetiologies. REACH/REACH-2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04f0b3683a78aa325a2a21f24c0f398a
https://boris.unibe.ch/157994/1/liv.14994.pdf
https://boris.unibe.ch/157994/1/liv.14994.pdf
Publikováno v:
Neurobiology of Disease, Vol 22, Iss 2, Pp 294-301 (2006)
There is clear evidence that an inflammatory reaction is mounted within the CNS following trauma, stroke, infection and seizures, thus augmenting brain damage. Furthermore, chronic inflammation of the CNS is implicated in many neurodegenerative disor
Externí odkaz:
https://doaj.org/article/89fa581e1d9744969a16c8bfea4cc312
Autor:
Madiha Ghias, Kenyon D. Ogburn, Astra M. Liepa, Robert Goodloe, Zhanglin Lin Cui, Jessica A. Davis, Lisa M. Hess, Xiaohong Li
Publikováno v:
Journal of the National Comprehensive Cancer Network. 17:HSR19-083
Background: Previous work has demonstrated treatment (tx) heterogeneity in the care of patients with aGC/GEJ. This study was designed to examine heterogeneity temporal trends and OS in patients with aGC/aGEJ in the United States from 2011 to 2018. Me
Autor:
Kenyon D. Ogburn, Chunxiao Wang, S. Qin, Richard S. Finn, Peter R. Galle, Ryan C. Widau, Andrew X. Zhu
Publikováno v:
Annals of Oncology. 31:S702
Autor:
Zhiyou Wang, Patricia Soteropoulos, Kenyon D. Ogburn, Maria E. Figueiredo-Pereira, Virginie Aris
Publikováno v:
Journal of Biological Chemistry. 281:21377-21386
Many neurodegenerative disorders are characterized by two pathological hallmarks: progressive loss of neurons and occurrence of inclusion bodies containing ubiquitinated proteins. Inflammation may be critical to neurodegeneration associated with ubiq
Autor:
Michael Overduin, Scott D. Emr, Tonny de Beer, Tatiana G. Kutateladze, William T Watson, Christopher G. Burd, Kenyon D. Ogburn
Publikováno v:
Molecular Cell. 3(6):805-811
Recognition of phosphatidylinositol 3-phosphate (PtdIns(3)P) is crucial for a broad range of cellular signaling and membrane trafficking events regulated by phosphoinositide (PI) 3-kinases. PtdIns(3)P binding by the FYVE domain of human early endosom
Publikováno v:
The Journal of biological chemistry. 281(32)
Many neurodegenerative disorders, such as Parkinson disease, exhibit inclusion bodies containing ubiquitinated proteins. The mechanisms implicated in this aberrant protein deposition remain elusive. In these disorders signs of inflammation are also a
Publikováno v:
Neurobiology of Disease, Vol 22, Iss 2, Pp 294-301 (2006)
There is clear evidence that an inflammatory reaction is mounted within the CNS following trauma, stroke, infection and seizures, thus augmenting brain damage. Furthermore, chronic inflammation of the CNS is implicated in many neurodegenerative disor
Autor:
Paolo Abada, Josep M. Llovet, Yann Touchefeu, Tae-You Kim, Peter R. Galle, Jean-Marc Phelip, Vittorina Zagonel, Andrew X. Zhu, Richard S. Finn, Kenyon D. Ogburn, Guido Stirnimann, Mark Karwal, Masatoshi Kudo, Jiri Tomasek, Chunxiao Wang, Denis Pezet, Ryan C. Widau, Su-Jin Koh, Tsai-Sheng Yang
Publikováno v:
Web of Science
569 Background: REACH (NCT01140347) and REACH-2 (NCT02435433) were global, randomized, blinded, placebo (PL)-controlled phase 3 trials of ramucirumab (RAM) in pts with advanced HCC following sorafenib. REACH-2 limited enrollment to pts with AFP ≥40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::288545322fac7a532864d17c7925f3e5
https://publons.com/wos-op/publon/33976175/
https://publons.com/wos-op/publon/33976175/